Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The clinical failure of two large mGluR5-antagonist programmes in Fragile X syndrome has forced drug developers to rethink trial design and target selection for neurodevelopmental indications.
